Beijing Bio-tech Company EdiGene Raised ¥81.50 Million in a Series Pre-B2 Round Funding Jointly by IDG Capital and Lily Asia Ventures

0
Beijing Bio-tech Company EdiGene Raised ¥81.50 Million in a Series Pre-B2 Round Funding Jointly by IDG Capital and Lily Asia Ventures
Beijing Bio-tech Company EdiGene Raised ¥81.50 Million in a Series Pre-B2 Round Funding Jointly by IDG Capital and Lily Asia Ventures

Beijing bio-tech company EdiGene raised ¥81.50 million in a series Pre-B2 round funding jointly by IDG Capital and Lily Asia Ventures. The investment will be used to the continuous launch of its product line.

Established in 2015, EdiGene focuses on using gene editing technology to develop new treatment that traditional treatments fail to cure and provide more innovative solutions for new drug development.

South Africa Today


Read more at VolaNews

Disclaimer: The views of authors published on South Africa Today are their own and do not necessarily represent the views of South Africa Today. By viewing, visiting, using, or interacting with SouthAfricaToday.net, you are agreeing to all the provisions of the Terms of Use Policy and the Privacy Policy.